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Available online 7 January 2017Background: Little is known about drug use patterns among people livingwith HIV in comparison to an uninfect-
ed group in the general population. The aim of this study was to investigate the association between legal and
illegal drug use and HIV infection in a nationally representative sample of adults in the United States.
Methods: Public use data files (2005–2014) from the National Survey on Drug Use and Health (NSDUH) were
used. Respondents were asked whether a medical professional had ever told them that they had HIV/AIDS.
Ever (lifetime), past-year, and pastmonth use of cigarettes, alcohol,marijuana, cocaine, heroin, hallucinogens, in-
halants, and nonmedical use of psychotherapeuticswas assessed. Logistic regressionwas used to estimate adjust-
ed odds ratios (aOR) of the relationship between drug use and HIV infection, adjusting for demographics.
Results: Of 377,787 respondents age 18 and older, 548 (0.19%) were categorized as HIV-infected. Ever use of cig-
arettes, tobacco, marijuana, cocaine, heroin, hallucinogens, inhalants, and psychotherapeutics was higher in HIV-
infected individuals compared to HIV-uninfected individuals after adjustment for sex, age, race/ethnicity, educa-
tion, total family income, andmarital status. Past year and past month use was also higher for HIV-infected indi-
viduals for all substances aside from alcohol.
Conclusions: In a nationally representative sample, there are higher levels of drug use and DSM-IV dependence
among the HIV-infected population compared to the HIV-uninfected population. This is of concern because
drug use and dependence can impede engagement in HIV care and adherence to antiretroviral therapy.





Drug use and Human Immunodeficiency Virus (HIV) have been
closely linked since the start of the HIV epidemic. In the United States,
over 180,000 people with HIV who inject drugs have died over the
course of the epidemic, accounting for N25% of total deaths among peo-
ple with Acquired Immune Deficiency Syndrome (AIDS) (Centers forartment of Epidemiology, 722
ed States.
a2@columbia.edu
columbia.edu (S.S. Martins).Disease Control and Prevention, 2015). Drug use is a well-established
risk factor of HIV infection. Of an estimated 44,073 people newly diag-
nosed with HIV infection in the United States in 2014, approximately
6% were attributed to injection drug use and an additional 3% were
due to injection drug use in combinationwithmale-to-male sexual con-
tact (Centers for Disease Control and Prevention, 2014). Recently, an
outbreak in Indiana of 181 new cases of HIV infection in a community
of 4200 people over 12 months in 2014–2015 was linked to injection
use of prescription opiates (Conrad et al., 2015). Although injection
drug use can directly lead to HIV transmission via the sharing of drug
preparation or injection equipment, drinking, smoking, or inhaling
drugs such as alcohol, cocaine, and methamphetamine can further
40 S. Shiau et al. / Addictive Behaviors 68 (2017) 39–44increase HIV infection risk by adversely affect decision making and in-
creasing risky sexual behavior (Baggaley, Boily, White, & Alary, 2006;
Hudgins, McCusker, & Stoddard, 1995; Molitor, Truax, Ruiz, & Sun,
1998; Purcell, Parsons, Halkitis, Mizuno, & Woods, 2001).
In addition to increasing the risk of HIV transmission, for those al-
ready infected with HIV, drug use poses several health challenges.
Some evidence indicates substance use can alter HIV disease progres-
sion by immune modulation and increasing HIV viral load (Kapadia,
Vlahov, Donahoe, & Friedland, 2005). In addition, drug use can negative-
ly affect adherence to HIV treatment and engagement with health care
(Azar, Springer, Meyer, & Altice, 2010; Hinkin et al., 2007), leading to
adverse clinical outcomes. As a result, the management of HIV in drug
users requires a careful consideration of many factors, including comor-
bid medical and mental health conditions, medication side effects and
toxicities, and drug interactions.
Existing studies on HIV and drug use in the United States primarily
report on HIV infection rates among injection drug users in comparison
to non-injection drug users (Spiller, Broz, Wejnert, Nerlander, &
Paz-Bailey, 2015; Strathdee & Stockman, 2010) or on the prevalence
of drug use among a population with HIV (Galvan et al., 2002; Ompad
et al., 2016). Few studies, however, have specifically compared drug
use patterns among people living with HIV to people without HIV in
the general United States population. Furthermore, it is unclear if the
burden of HIV and substance use varies across sub-groups of the popu-
lation, such as young adults or racial/ethnic minorities. Carefully study-
ing these patternsmay identify specific groups of drugusers to target for
HIV prevention, as well as drug users with HIV to target for substance
abuse prevention or treatment as well as HIV care. In this study, we in-
vestigated the association between legal and illegal drug use andHIV in-
fection in a nationally representative sample of adults in the United
States. In addition, we assessed the association between HIV and illegal
drug use across age, race/ethnicity, and sex groups.
2. Materials and methods
2.1. Data source
We used data from the National Survey on Drug Use and Health
(NSDUH), an annual national survey sponsored by the Substance
Abuse and Mental Health Services Administration (SAMHSA) that eval-
uates the use of legal and illegal drugs in thenoninstitutionalizedUnited
States citizen population, age 12 and older (Substance Abuse and
Mental Health Services Administration, 2005–2014). Each year, house-
holds are randomly selected to participate in the NSDUH and data are
collected using questionnaires administered through face-to-face inter-
views. Sampling weights were created to account for probability of se-
lection into the sample, correct for nonresponse, and adjust for known
population distributions (Substance Abuse and Mental Health Services
Administration, 2012). Public use data files from 2005 to 2014 were
combined for this analysis. From a total of 560,099 observations from
all years, we excluded 176,879 participants under the age of 18 and an
additional 5433 with missing/unknown HIV infection status (only
0.97% of the total sample), leaving uswith a total of 377,787 participants
for analysis.
2.2. Measures
The following socio-demographic characteristics were considered in
this analysis: sex, age, race/ethnicity, education, total family income,
and marital status. Race/ethnicity included the following categories:
non-Hispanic White, non-Hispanic Black, Hispanic, and Other (Native
American, Native Hawaiian or Pacific Islander, Asian, and more than
one race). New questions asking about 20 lifetime health conditions
have been added to the NSDUH questionnaire since 2005. Respondents
were asked whether doctors or other medical professionals had ever
told them that they had HIV/AIDS andwere categorized as HIV-infectedif they responded yes. Ever (lifetime) use, past-year use, pastmonth use,
was assessedwith a dichotomous (yes/no) variable for a number of sub-
stances including cigarettes, alcohol, marijuana, cocaine, heroin, halluci-
nogens, inhalants, and non-medical psychotherapeutics (analgesics
including prescription opioids, stimulants including methamphet-
amine, sedatives, and tranquilizers). Past-year DSM-IV-TR dependence
(met three or more of seven DSM-IV dependence criteria) was also
assessed (American Psychiatric Association, 2000). Any illegal drug
use and DSM-IV dependence was also assessed.
2.3. Statistical analyses
First, descriptive characteristics of the sample were calculated strat-
ified by HIV-infection using weighted cross-tabulations. Next, drug use
characteristics were compared between HIV-infection groups using
weighted-cross tabulations. Chi-squared tests were used to determine
differences in characteristics by HIV infection group. Weighted logistic
regression was then used to estimate unadjusted odds ratios (OR) and
95% confidence intervals of drug use comparing HIV-infected partici-
pants to HIV-uninfected participants. Multivariablemultinomial logistic
regression was then used to generate adjusted odds ratios (aOR) to
evaluate the relationship between drug use and HIV infection, adjusting
for potential confounders including sex, age, race/ethnicity, education,
total family income, and marital status. Finally, to better understand
the burden of substance use and HIV across sub-groups, we compared
the prevalence of past year illegal drug use between HIV-infected and
uninfected participants within sub-groups, including sex (male vs. fe-
male), age (18–25 vs. 26–34 vs. 35–49 vs. 50), and race/ethnicity
(non-Hispanic White, non-Hispanic Black, and Hispanic) using Chi-
squared tests. The Other race/ethnicity group was excluded due to
small numbers. Weighted logistic regression was used to calculate the
OR and 95% confidence intervals of illegal drug use comparing HIV-in-
fected participants to HIV-uninfected participants within sub-groups,
adjusted for other demographic variables. Data were analyzed with
SAS 9.4 (Cary, NC, USA) and adjusted for weighting and clustering to re-
flect the complex design of the NSDUH sample. All p-values are 2-tailed
and p-values b 0.05 were considered statistically significant.
3. Results
3.1. Demographic characteristics by HIV infection group
Data on characteristics of 377,787 respondents age 18 and older are
presented in Table 1, stratified by HIV infection group. A total of 548
(0.19% weighted) adults were categorized as HIV-infected. Sex, age,
race/ethnicity, family income, and marital status were significantly dif-
ferent between the HIV-uninfected and HIV-infected group. While sex
was balanced in the HIV-uninfected group (48% male), 80% of the HIV-
infected group was male (p b 0.0001). A higher proportion of the HIV-
infected group was 35–49 years of age compared to the HIV-uninfected
group (41.4 vs. 27.5%, p b 0.0001). In addition, a greater proportion of
the HIV-infected group was non-Hispanic Black (29.2 vs. 11.4%,
p b 0.0001) and Hispanic (18.8 vs. 13.9%, p b 0.0001) compared to the
HIV-uninfected group. Forty percent of the HIV-infected group had a
total family income b$19,000 compared to 18.3% in the HIV-uninfected
group. A larger proportion of the HIV-infected group had never been
married compared to the HIV-uninfected group (68.1 vs. 26.2%,
p b 0.0001).
3.2. Drug use characteristics by HIV infection group
A higher proportion of the HIV-infected group reported ever use of
cigarettes, tobacco, alcohol, marijuana, cocaine, heroin, hallucinogens,
inhalants, and non-medical psychotherapeutics, and any illegal drug
use compared to the HIV-uninfected group (Table 2). Three-quarters
of the HIV-infected participants reported ever using marijuana
Table 1
Selected characteristics of participants living without and with HIV/AIDS age 18 and older (N= 377,787). Percentages are weighted to be nationally representative.
Data from the 2005 to 2014 National Survey on Drug Use and Health, United States.
Characteristics Total sample N = 377.787 HIV-uninfected N = 377.239 HIV-infected N = 548
N Wt% (SE) N Wt% (SE) N Wt% (SE) p-Value
Sex
Male 175,197 48.1 (0.13) 174,790 48.0 (0.13) 407 80.1 (2.2) b0.0001
Female 202,590 51.9 (0.13) 202,449 52.0 (0.13) 141 19.9 (2.2)
Age
18-25 178,024 14.6 (0.09) 177,898 14.7 (0.09) 126 5.7 (0.7) b0.0001
26-34 58,034 15.8 (0.09) 57,950 15.8 (0.09) 84 15.6 (2.0)
35-49 80,984 27.5 (0.13) 80,743 27.5 (0.13) 241 41.4 (2.9)
50+ 60,745 42.0 (0.18) 60,648 42.1 (0.18) 97 37.3 (2.8)
Race/ethnicity
Non-Hispanic White 241,855 58.0 (0.19) 241,598 68.1 (0.18) 257 51.5 (3.7) b0.0001
Non-Hispanic Black 46,083 11.5 (0.13) 45,896 11.4 (0.13) 187 29.2 (3.3)
Hispanic 57,964 13.9 (0.13) 57,870 13.9 (0.13) 94 18.8 (2.6)
Other 31,885 6.6 (0.10) 31,875 6.6 (0.10) 10 0.5 (0.4)
Education
Less than high school 294,313 71.2 (0.18) 293,897 71.2 (0.18) 416 67.0 (3.6) 0.226
High school graduate or more 83,474 28.8 (0.18) 83,342 28.7 (0.18) 132 33.0 (3.6)
Total family income b0.0001
b$19,000 94,937 18.4 (0.14) 94,707 18.3 (0.14) 230 40.1 (3.6)
$20,000–39,000 130,384 32.9 (0.14) 130,214 32.9 (0.140) 170 29.7 (2.7)
$40,000–74,000 60,878 17.4 (0.13) 60,820 17.5 (0.13) 58 11.2 (2.2)
$75,000+ 91,588 31.4 (0.20) 91,498 31.4 (0.20) 90 19.1 (3.2)
Marital status
Currently married 139,779 54.0 (0.17) 139,722 54.0 (0.17) 57 14.1 (2.3) b0.0001
Previously married 45,350 19.8 (0.12) 45,248 19.8 (0.12) 102 17.8 (2.2)
Never married 192,658 26.3 (0.13) 192,269 26.2 (0.13) 389 68.1 (2.8)
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the HIV-infected participants reported ever cocaine use (57.6%), ever
hallucinogen use (49.2%), ever inhalant use (42.7%), and ever non-med-
ical psychotherapeutic use (47.4%). Over 80% of the HIV-infected partic-
ipants reported ever using illegal drugs compared to just under 50% of
the HIV-uninfected participants. Past year and past month use of all
drugs aside from alcohol was significantly higher in the HIV-infected
group compared to the HIV-uninfected group. Close to half (46.1%) of
the HIV-infected participants reported any past year illegal drug use
compared to 14.7% of the HIV-uninfected participants (p b 0.0001). A
third (36%) of the HIV-infected participants reported any past month il-
legal drug use compared to 8.6% of the HIV-uninfected participants
(p b 0.0001).
3.3. HIV and drug use: logistic regression results
To adjust for potential confounding of the association between HIV
and drug use, we conducted weighted multinomial logistic regression
analyses adjusted for sex, age, race/ethnicity, education, total family in-
come, and marital status (Table 3). In adjusted analyses, ever use of all
drugs was higher in HIV-infected participants compared to HIV-unin-
fected participants, including cigarettes (aOR: 1.63, 95% CI: 1.22, 2.17),
tobacco (aOR: 1.50, 95% CI: 1.10, 2.05), alcohol (aOR: 2.47, 95% CI:
1.40, 4.33), marijuana (aOR: 3.58, 95% CI: 2.75, 4.66), cocaine (aOR:
5.49, 95% CI: 4.10, 7.35), heroin (OR: 3.84, 95% CI: 2.47, 5.98), hallucino-
gens (aOR: 4.55, 95% CI: 3.37, 6.14), inhalants (aOR: 6.85, 95% CI: 5.12,
9.15), psychotherapeutics (aOR: 3.11, 95% CI: 2.31, 4.18). Ever use of
any illegal drug use was N4 times higher in HIV-infected participants
compared to HIV-uninfected participants (aOR: 4.62, 95% CI: 3.39,
6.29). Past year use of cigarettes (aOR: 2.15, 95% CI: 1.67, 2.77), tobacco
(aOR: 1.59, 95% CI: 1.24, 2.05), marijuana (aOR: 3.16, 95% CI: 2.41, 4.16),
cocaine (aOR: 4.56, 95% CI: 3.16, 6.58), heroin (aOR: 3.64, 95% CI: 1.08,
12.25), hallucinogens (aOR: 3.76, 95% CI: 2.28, 6.22), inhalants (aOR:
14.69, 95% CI: 9.90, 21.79), and non-medical psychotherapeutics (aOR:
2.73, 95% CI: 1.93, 3.86) was significantly higher among those with
HIV-infection compared to those without HIV-infection, after adjust-
ment for sex, age, race/ethnicity, education, total family income, and
marital status. Resultswere very similar for pastmonth use of cigarettes(aOR: 2.09, 95% CI: 1.63, 2.68), tobacco (aOR: 1.63, 95% CI: 1.29, 2.06),
marijuana (aOR: 3.31, 95% CI: 2.49, 4.40), cocaine (aOR: 5.27, 95% CI:
3.25, 8.55), heroin (aOR: 6.36, 95% CI: 1.80, 22.44), hallucinogens
(aOR: 4.04, 95% CI: 1.86, 8.80), inhalants (aOR: 16.94, 95% CI: 10.22,
28.06), and non-medical psychotherapeutics (aOR: 3.09, 95% CI: 1.95,
4.90). Past year DSM-IV dependence of any illicit drug use was 4 times
higher in HIV-infected participants compared to HIV-uninfected partic-
ipants (aOR 4.34, 95% CI: 2.87, 6.57).
3.4. Past year illegal drug use in sub-groups
The prevalence of past-year illegal drug use was greater in males
with and without HIV-infection than females (Table 4), with half of all
males with HIV-infection using illegal drugs in the past year. The associ-
ation between HIV and past year illegal drug use was higher in males
(OR: 4.19, 95% CI: 3.16, 5.56) compared to females (OR: 2.76, 95% CI:
1.64, 4.66). Across all age groups, the prevalence of past-year illegal
drug use was higher in HIV-infected participants compared to HIV-un-
infected participants (Table 4). The prevalence decreased from 62.7%
among the youngest HIV-infected group to 36.4% in the oldest HIV-in-
fected group. In weighted logistic regression models, the odds of past
year illegal drug use was 2.76 (95% CI: 1.66, 4.58), 3.33 (95% CI: 1.82,
6.09), 3.63 (95% CI: 2.47, 5.35), and 4.83 (95% CI: 2.71, 8.58) times
higher in HIV-infected adults than HIV-uninfected adults for those 18–
25 years, 26–34 years, 35–49 years, and N50 years, respectively. The
prevalence of past-year illegal drug use was significantly higher in
HIV-infected participants compared to HIV-uninfected participants in
all race/ethnicity groups (Table 4), and similar between race/ethnicity
groups. The odds of past year illegal drug use was similar across race/
ethnicity groups, including among non-Hispanic Whites (OR: 4.37,
95% CI: 2.96, 6.44), non-Hispanic Blacks (OR: 3.35, 95% CI: 2.13, 5.26),
and Hispanics (OR: 3.94, 95% CI: 2.05, 7.57).
4. Discussion
Our study compares drug use characteristics in HIV-infected individ-
uals toHIV-uninfected individuals in a nationally representative sample.
We found higher levels of reported ever drug use among HIV-infected
Table 2
Drug use characteristics of participants living without and with HIV/AIDS age 18 and older (N= 377,787). Percentages are weighted to be nationally representative.
Data from the 2005 to 2014 National Survey on Drug Use and Health, United States.
Characteristics Total sample N = 377.787 HIV-uninfected N = 377.239 HIV-infected N = 548
N Wt% (SE) N Wt% (SE) N Wt% (SE) p-Value
Ever
Cigarette 254,248 68.7 (0.12) 253,813 68.7 (0.12) 435 79.4 (2.4) b0.0001
Any tobacco 274,301 73.4 (0.11) 273,850 73.4 (0.11) 451 83.3 (2.2) 0.0001
Alcohol 330,728 87.5 (0.10) 330,215 87.5 (0.10) 513 94.6 (1.5) 0.001
Marijuana 189,121 44.6 (0.14) 188,715 44.5 (0.14) 406 76.7 (2.4) b0.0001
Cocaine 60,337 15.9 (0.10) 60,069 15.9 (0.10) 268 57.6 (3.0) b0.0001
Heroin 7230 1.78 (0.03) 7175 1.76 (0.03) 55 11.4 (2.1) b0.0001
Hallucinogens 68,278 15.8 (0.09) 68,050 15.7 (0.09) 228 49.2 (3.1) b0.0001
Inhalants 37,994 8.7 (0.08) 37,790 8.6 (0.08) 204 42.7 (2.9) b0.0001
Psychotherapeutics 96,140 21.6 (0.09) 95,890 21.5 (0.09) 250 47.4 (3.3) b0.0001
Any illegal drug use 209,431 49.6 (0.13) 208,981 49.6 (0.13) 450 83.8 (2.1) b0.0001
Past year
Cigarette 139,303 28.5 (0.13) 139,001 28.4 (0.13) 302 50.9 (3.0) b0.0001
Any tobacco 164,607 34.5 (0.13) 164,286 34.4 (0.13) 321 53.0 (3.0) b0.0001
Alcohol 283,089 70.5 (0.15) 282,675 70.5 (0.15) 414 75.5 (2.9) 0.098
Marijuana 72,425 11.2 (0.08) 72,215 11.1 (0.08) 210 34.2 (2.9) b0.0001
Cocaine 12,849 2.0 (0.03) 12,769 2.0 (0.03) 80 12.9 (2.0) b0.0001
Heroin 1574 0.24 (0.01) 1564 0.24 (0.01) 10 1.7 (1.0) 0.0002
Hallucinogens 13,346 1.5 (0.02) 13,303 1.5 (0.02) 43 5.3 (1.3) b0.0001
Inhalants 3362 0.46 (0.02) 3298 0.44 (0.02) 64 9.9 (1.6) b0.0001
Psychotherapeutics 35,759 6.03 (0.06) 35,655 6.01 (0.06) 104 16.1 (2.3) b0.0001
Any illegal drug use 89,037 14.7 (0.10) 88,753 14.7 (0.10) 284 46.1 (2.9) b0.0001
Past month
Cigarette 116,544 24.6 (0.13) 116,273 24.5 (0.13) 271 45.7 (3.1) b0.0001
Any tobacco 136,543 29.3 (0.13) 136,258 29.3 (0.13) 285 47.3 (3.1) b0.0001
Alcohol 222,369 55.9 (0.15) 222,024 55.8 (0.15) 345 61.9 (3.1) 0.056
Marijuana 43,769 6.8 (0.06) 43,618 6.7 (0.06) 151 24.9 (2.5) b0.0001
Cocaine 4159 0.74 (0.02) 4121 0.73 (0.02) 38 7.3 (1.6) b0.0001
Heroin 648 0.11 (0.007) 642 0.11 (0.006) 6 1.5 (1.0) b0.0001
Hallucinogens 3391 0.40 (0.01) 3376 0.40 (0.01) 15 1.8 (0.67) b0.0001
Inhalants 849 0.15 (0.01) 815 0.14 (0.01) 34 6.0 (1.4) b0.0001
Psychotherapeutics 14,769 2.6 (0.04) 14,715 2.5 (0.04) 54 8.8 (1.8) b0.0001
Any illegal drug use 52,693 8.6 (0.07) 52,489 8.6 (0.07) 204 36.0 (2.9) b0.0001
Past year DSM-IV dependence
Alcohol 18,861 3.4 (0.04) 18,817 3.4 (0.04) 44 6.1 (1.5) 0.018
Marijuana 7733 0.96 (0.02) 7708 0.95 (0.02) 25 2.9 (0.8) b0.0001
Cocaine 1838 0.35 (0.01) 1809 0.34 (0.01) 29 4.6 (1.3) b0.0001
Heroin 882 0.14 (0.008) 876 0.14 (0.008) 6 1.5 (1.0) b0.0001
Hallucinogens 360 0.04 (0.003) 356 0.04 (0.003) 4 0.24 (0.14) 0.0002
Inhalants 75 0.01 (0.002) 71 0.01 (0.002) 4 0.59 (0.35) b0.0001
Psychotherapeutics 4121 0.64 (0.02) 4102 0.63 (0.02) 19 2.8 (0.8) b0.0001
Any illicit drug 12,812 1.8 (0.03) 12,745 1.8 (0.03) 67 10.2 (1.8) b0.0001
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year and past month use, the HIV-infected group consistently reported
higher use of all substances other than alcohol compared to the HIV-un-
infected group, even after adjustment for demographic variables. This
study is of particular importance as few studies have estimated drug
usage among HIV-infected populations in comparison to the general
population. The majority of epidemiologic studies report on HIV infec-
tion rates among injection drug users in comparison to non-injection
drug users (Spiller et al., 2015; Strathdee & Stockman, 2010) or on the
prevalence of drug use among a population with HIV (Galvan et al.,
2002; Ompad et al., 2016).
Ourfindingof both higher lifetime and recent drug use inHIV-infect-
ed adults versus uninfected adults is of great concern. Drug use can af-
fect HIV disease progression, impede engagement in care, and affect
adherence to antiretroviral therapy. Specific drugs have been shown
to affect disease progression and quality of life even among those with
suppressed virus on treatment. A study of suppressedHIV-infected indi-
viduals found users of methamphetamine to have greater CD4 T-cell
and CD8T-cell proliferation aswell as exhaustion of the immune system
(Massanella et al., 2015). In infected adults receiving care, those with
current illicit drug use and polysubstance use have decreased mental
and physical health-related quality of life (Korthuis et al., 2008). Unfor-
tunately, drug use can negatively affect adherence to HIV treatment and
engagement with health care (Arnsten et al., 2002; Azar et al., 2010;Hinkin et al., 2007; Nolan et al., 2011). Life expectancy consequences
of HIV and drug use may also exist (Helleberg et al., 2013; Marcus et
al., 2016; Samji et al., 2013). A recent study of HIV-infected adults in
the Kaiser Permanente cohort in 1996–2011 and matched HIV-unin-
fected adultswhich estimated a life expectancy gap for the HIV-infected
adults, particularly among those who use injection drugs (Marcus et al.,
2016). Treatment considerations are also needed for HIV-infected drug
users, especially around drug interactions when treating both drug ad-
diction and HIV-infection. For example, the concentration of metha-
done, used to treat opioid addictions and reduce pain, is decreased in
blood when used in combination with certain antiretroviral regimens
(McCance-Katz, 2005).
Apart from adverse effects on an individual's health, substance use
among people living with HIV has implications for continued spread
of HIV through risky sexual behavior. Drug use is a strong predictor of
poor adherence and, consequently, failure tomaintain viral suppression
(Arnsten et al., 2002; Cropsey et al., 2016). Increases in viral load have
been shown to be associated with an increased risk of HIV transmission
(Attia, Egger, Muller, Zwahlen, & Low, 2009; Gray et al., 2001).
We did not find past year and past month alcohol use to be signifi-
cantly different between the HIV-infected and HIV-uninfected groups.
This finding is consistent with a national probability survey of HIV-in-
fected adults receivingmedical care in the United States which estimat-
ed 53.4% of the population of HIV-infected persons to have consumed
Table 3
Unadjusted and adjustedweighted binary logistic regressionmodel for the association be-
tween HIV status and drug use.
Data from the 2005 to 2014 National Survey on Drug Use and Health, United States.
Characteristics Unadjusted OR (95% CI)
(HIV+ vs. HIV−)
⁎Adjusted OR (95% CI)
(HIV+ vs. HIV−)
Ever
Cigarette 1.76 (1.32, 2.34) 1.63 (1.22, 2.17)
Any tobacco 1.80 (1.33, 2.44) 1.50 (1.10, 2.05)
Alcohol 2.51 (1.42, 4.44) 2.47 (1.40, 4.33)
Marijuana 4.09 (3.15, 5.33) 3.58 (2.75, 4.66)
Cocaine 7.19 (5.64, 9.16) 5.49 (4.10, 7.35)
Heroin 7.21 (4.75, 10.95) 3.84 (2.47, 5.98)
Hallucinogens 5.18 (4.07, 6.61) 4.55 (3.37, 6.14)
Inhalants 7.92 (6.27, 10.00) 6.85 (5.12, 9.15)
Psychotherapeutics 3.29 (2.53, 4.26) 3.11 (2.31, 4.18)
Any illegal drug use 5.26 (3.89, 7.12) 4.62 (3.39, 6.29)
Past year
Cigarette 2.61 (2.06, 3.30) 2.15 (1.67, 2.77)
Any tobacco 2.15 (1.70, 2.72) 1.59 (1.24, 2.05)
Alcohol 1.29 (0.95, 1.74) 1.33 (0.93, 1.90)
Marijuana 4.15 (3.24, 5.32) 3.16 (2.41, 4.16)
Cocaine 7.24 (5.13, 10.21) 4.56 (3.16, 6.58)
Heroin 7.17 (2.17, 23.63) 3.64 (1.08, 12.25)
Hallucinogens 3.60 (2.15, 6.02) 3.76 (2.28, 6.22)
Inhalants 24.75 (16.99, 36.06) 14.69 (9.90, 21.79)
Psychotherapeutics 3.01 (2.16, 4.18) 2.73 (1.93, 3.86)
Any illegal drug use 4.98 (3.96, 6.26) 3.98 (3.07, 5.16)
Past month
Cigarette 2.59 (2.03, 3.31) 2.09 (1.63, 2.68)
Any tobacco 2.17 (1.71, 2.76) 1.63 (1.29, 2.06)
Alcohol 1.28 (0.99, 1.66) 1.21 (0.90, 1.63)
Marijuana 4.60 (3.54, 5.99) 3.31 (2.49, 4.40)
Cocaine 10.70 (6.68, 17.15) 5.27 (3.25, 8.55)
Heroin 14.54 (4.06, 52.03) 6.36 (1.80, 22.44)
Hallucinogens 4.59 (2.16, 9.76) 4.04 (1.86, 8.80)
Inhalants 45.40 (27.94, 73.77) 16.94 (10.22, 28.06)
Psychotherapeutics 3.70 (2.39, 5.71) 3.09 (1.95, 4.90)
Any illegal drug use 5.98 (4.68, 7.64) 4.45 (3.39, 5.82)
Past year DSM-IV dependence
Alcohol 1.86 (1.10, 3.12) 1.17 (0.69, 1.99)
Marijuana 3.12 (1.80, 5.41) 2.31 (1.32, 4.06)
Cocaine 14.00 (7.88, 24.86) 6.01 (3.22, 11.21)
Heroin 11.02 (2.97, 40.91) 5.19 (1.39, 19.31)
Hallucinogens 6.32 (2.09, 19.17) 5.74 (1.84, 17.94)
Inhalants 70.66 (22.29, 224.02) 64.29 (14.60, 283.20)
Psychotherapeutics 4.43 (2.50, 7.87) 3.95 (2.17, 7.20)
Any illicit drug 6.14 (4.16, 9.07) 4.34 (2.87, 6.57)
⁎ Adjusted for sex (reference = female), age (reference = 50+), race/ethnicity (refer-
ence= non-Hispanic white), education (reference= high school graduate ormore), total
family income (reference = $75,000+), marital status (reference = currently married).
Table 4
Past year illegal druguse of participants livingwithout andwithHIV/AIDS age 18 and older
(N = 377,787) stratified by sex, age, and race/ethnicity. Percentages are weighted to be
nationally representative.





N Wt% (SE) N Wt% (SE) p-Value
Sex
Male 48,218 17.7 (0.2) 231 50.6 (3.4) b0.0001
Female 40,535 11.9 (0.1) 53 28.2 (5.0) b0.0001
Age
18-25 61,236 35.1 (0.2) 79 62.7 (6.2) b0.0001
26-34 12,699 22.0 (0.3) 53 57.9 (7.9) b0.0001
35-49 11,054 13.1 (0.1) 114 48.2 (4.6) b0.0001
50+ 3764 5.8 (0.1) 38 36.4 (6.5) b0.0001
Race/ethnicity
Non-Hispanic White 58,238 14.9 (0.1) 142 49.8 (4.4) b0.0001
Non-Hispanic Black 11,405 16.4 (0.3) 86 41.9 (5.4) b0.0001
Hispanic 11,626 13.5 (0.2) 47 43.2 (7.3) b0.0001
43S. Shiau et al. / Addictive Behaviors 68 (2017) 39–44alcohol in the past month, similar to a general population estimate of
53.5% reported by the Substance Abuse and Mental Health Services Ad-
ministration (SAMHSA) (Galvan et al., 2002). Despite no elevated alco-
hol use in the HIV-infected group, alcohol use may be uniquely harmful
in this population. A recent analysis of data from the Veterans Aging Co-
hort study found that HIV-infected adults had a higher risk of mortality
or physiological injury in comparison to HIV-uninfected individuals,
even among lower alcohol consumption levels and among individuals
with suppressed viral load (Justice et al., 2016).
Our data suggests the combination of HIV and drug use may affect
sub-groups of the population. Consistent with other national estimates
indicating that HIV has a disproportionate impact on racial and ethnic
minorities in the United States (Pellowski, Kalichman, Matthews, &
Adler, 2013), in our study almost 50% of the HIV-infected group includ-
ed non-Hispanic Blacks and Hispanics in comparison to 25% of the HIV-
uninfected group. These differences support that interventions, includ-
ing HIV and substance use prevention, need to be specifically tailored
for affected populations. Although the association between HIV and
drug use is higher in males than females, it still remains elevated for
women with HIV compared to women without HIV. Globally, female
HIV-infected drug users may not regularly engage in HIV care and re-
ceive the benefits of ART and specific implementation approaches are
needed that consider structural and contextual level barriers to care
(Metsch et al., 2015). While drug use was more prevalent in all age
groups comparing HIV-infected individuals to uninfected individuals,
young adults (age 18-25) with HIV are of particular concern. More
than 60% of HIV-infected young adults in our study used illegal drugs
in the past year. Young adults are undergoing many important
neurodevelopmental, psychosocial, and lifestyle changes and are more
prone to engaging in risky behaviors as compared to older age groups.
This can lead to challenges with adherence as they age. Drug use can
further disrupt this period of change (Chambers, Taylor, & Potenza,
2003; Degenhardt, Stockings, Patton, Hall, & Lynskey, 2016; Squeglia &
Gray, 2016) and lead to unexpected complications in this population
sub-group.
Although a major strength of this study is the nationally representa-
tive data source which allows us to compare an HIV-infected group to
an HIV-uninfected group, our study has several limitations. Our esti-
mate of HIV prevalence of 0.19% using combined 2015 to 2014 data
from NSDUH among adults 18 or older is slightly lower than other na-
tional estimates by the Centers for Disease Control (prevalence of
0.295% of people ages 13 and older living with diagnosed HIV infection
in the United States) (Hall et al., 2015). This may be due to the nature of
the self-reported HIV question which asked if the participant had been
told by a doctor or other health care professional that they had HIV/
AIDS. HIV-infected individuals misclassified as negative because they
are unaware of their infection status may be among the individuals at
greatest risk for not seeking care and receiving HIV testing and have
higher alcohol and drug use levels. The exclusion of incarcerated, insti-
tutionalized, and homeless adults from NSDUH may also contribute to
the underestimated HIV prevalence and limit the generalizability of
our study.
Findings from this study help us understand the highly intercon-
nected nature of drug use and HIV at the population level and have im-
portant implications with respect to HIV prevention, substance use
prevention and treatment, as well as HIV care and treatment. Public
health efforts are needed to screen and assess those infected with HIV
first for substance use to prevent progression to abuse/dependence,
then for substance dependence or abuse in order to link those in need
of assistance to care and treatment. For uninfected individuals that en-
gage in high-risk behaviors, the risk of HIV acquisition via needle expo-
sure or sexual exposure can be reduced through pre-exposure
prophylaxis (Landovitz, 2015) as well as other harm-reduction strate-
gies, though the effectiveness of pre-exposure prophylaxis highly de-
pends on adherence (Grant et al., 2010). A reduction in drug use may
have important implications for the health of people living with HIV.
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